logo
  

Merck Gets Positive CHMP Opinion For Keytruda Plus Chemotherapy For Triple-Negative Breast Cancer

Merck & Co., Inc. (MRK) said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer or TNBC in adults whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease.

The positive opinion is based on progression-free survival and overall survival results from the Phase 3 KEYNOTE-355 trial, which showed that treatment with KEYTRUDA in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin), as compared to chemotherapy alone, significantly improved progression-free survival and overall survival in these patient.

Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen hormone receptors, progesterone hormone receptors and overexpression of human epidermal growth factor receptor 2 (HER2). It is an aggressive type of breast cancer that characteristically has a high recurrence rate within the first five years after diagnosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and... Shares of Nestle SA were gaining around 4 percent in Swiss trading after the food and beverage giant on Wednesday raised its fiscal 2021 organic sales growth forecast after reporting higher sales in the first nine of the year. For the full year, the company now expects organic sales growth between 6 percent and 7 percent.
Follow RTT